Diabetic Retinopathy Market is Expected to Reach US$ XX Bn by 2025

28/gen/2019 13:42:55 Rajesh Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Diabetic Retinopathy Market is Expected to Reach US$ XX Bn by 2025, Due to Increasing Incedence of Blindness Caused by Diabetes

Analyst Speak:

 

The Diabetic Retinopathy Market is anticipated to reach about US$ XX Bn by 2025, and anticipated to expand at a CAGR over seven years of forecast period 2019-2025” owing to an increasing incidence of blindness caused by diabetes.

 

Precision Business Insights (PBI) in its report titled “Diabetic Retinopathy Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis and Forecast 2019-2025” assesses the market performance over seven years forecast period from 2019 to 2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

 

The diabetic retinopathy market size was accounted for US$ XX Bn in 2018 and anticipated to account for US$ XX Bn by 2025. Rise in healthcare infrastructure, increased diabetic population, rise in demand for early diagnosis are the main factors driving the diabetic retinopathy market. However, lack of primary infrastructure and insurance facility hinders the growth of market.

 

Diabetic retinopathy market segmented on the basis of type, drug class, and distribution channel.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-diabetic-retinopathy-market/#ulp-4H8Z4LpNMLEuOnnx

 

Anti VEGF Segment Expected to Dominate the Market

 

On the basis of management, the market is segmented into four categories namely, anti-VEGF treatment, laser surgery, intraocular steroid injection, and vitrectomy. Anti-VEGF segment dominated the market in 2018 owing to high applicability of these drugs in treatment of early diagnosis and mild to moderate cases of non-proliferative DR treatment, better treatment and faster recovery. The major anti-VEGF agents currently used include Eylea, Avastin, Lucentis, and Macugen. The increasing usage of Lucentis due to favorable outcomes further accelerates growth of the segment worldwide.

 

North America Accounts for Major Revenue Share for Diabetic Retinopathy Market

 

Precision Business Insights (PBI) diabetic retinopathy market report analyses the market in different regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. According to regional analysis, North America accounted for major revenue share due to high obesity rates making the population susceptible to diabetes. Europe is expected to be the major driver due to the presence of large patient pool. Asia Pacific is expected to account for an increased CAGR due to increased government initiatives in respect to diabetic management. China’s market is expected to witness rapid growth over the forecast period. Japan is the largest market in the Asia Pacific region mainly on account of the presence of high healthcare expenditure and rising disposable income. Moreover, growing usage of Lucentis is expected to drive market growth in this region

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-diabetic-retinopathy-market/#ulp-c654SbFYO64MsOhu

 

 

Market Strategies like Partnership Play Vital Role in Diabetic Retinopathy Market

 

Companies are adopting strategic initiatives such as acquisitions, mergers, geographical expansion and product development in order to advance their businesses and increase their outreach in the market. For instance, ThromboGenics initiated a partnership with Novartis (Alcon) to assist in the marketing and commercialization of JETREA outside the U.S.

 

Key players mentioned in this report are Novartis AG, Bayer Healthcare, Regeneron Pharmaceuticals Inc., ThromboGenics, Actavis Plc, Sirnaomics, Genentech, Alimera Sciences, Glycadia Pharmaceuticals, Ampio Pharmaceuticals, Kowa Group, and BCN Peptides among others.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-diabetic-retinopathy-market/#ulp-14mlyhjMGhVjZqa3

 

Detailed Segmentation

 

By Type

 

o   Proliferative Diabetic Retinopathy

o   Diabetic Macular Edema

 

By Drug Class Type

 

o   Corticosteroids

o   Anti-VEGF

o   Others

 

By Distribution Channel Type

 

o   Ophthalmic Clinics

o   Hospital Pharmacies

o   Retail Pharmacies

 

Geography

 

o   North America

§  U.S.

§  Canada

o   Europe

§  Germany

§  UK

§  France

§  Russia

§  Spain

§  Italy

§  Rest of Europe

o   Asia-Pacific

§  China

§  Japan

§  India

§  ASEAN

§  Rest of Asia Pacific

o   Latin America

§  Brazil

§  Mexico

§  Argentina

§  Chile

§  Rest of Latin America

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  Rest of MEA

 

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-diabetic-retinopathy-market/

 

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Contact Person: Rajesh Babu

Role: Marketing Lead

Email: sales@precisionbusinessinsights.com

Toll Free (US):+1-866-598-1553

Website @https://www.precisionbusinessinsights.com

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl